RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.

Prior treatment

• AF from a reversible cause (e.g., surgery, hyperthyroidism, sarcoidosis, or pericarditis, etc.)
• Enrollment in another investigational study evaluating another device, biologic or drug

Other illness

• Cardiac surgery or intervention within the past 90 days (e.g. percutaneous coronary intervention, ablation for ventricular arrhythmias, left atrial appendage occlusion devices, atrial septal defect closure devices, transcatheter aortic valve replacement)
• Myocardial infarction within the past 90 days
• Severe valvular disease or prosthetic valve(s)
• Decompensated heart failure or New York Heart Association (NYHA) Functional Class IV
• Any other contraindication to an intracardiac mapping and ablation of atrial arrhythmias

Other

• De Novo paroxysmal AF
• Presence of transvenous pacing or defibrillator leads or an atrial leadless pacemaker
• Contraindication to therapeutic anticoagulation
• Positive pregnancy test

• Suitable candidate for intra-cardiac mapping and ablation of atrial arrhythmias including atrial fibrillation, atrial flutter and/or atrial tachycardia
• Above eighteen (18) years of age or of legal age to give informed consent specific to state and national law
• Left atrial (LA) diameter ≤ 5.5 cm or LA volume index ≤ 50 mL/m2 (use whichever measure is available or if both available, use the lesser of the two to qualify)